Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts CRDF Hot Sheet
Join SI Premium – FREE
Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- MIND Technology (MIND) Misses Q1 EPS by 5c
- TechCreate Group faces NYSE American delisting proceedings
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
